Is CVX a buy, hold, or sell?
CVX carries a valuation grade of Buy. The trailing P/E of 30.3 sits 153% above the Energy sector median of 12.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $181–$263 — implying a +28% margin of safety at the current price of $174.05. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 45.6% earnings surprise. Analyst estimate revisions are trending upward.
What are CVX's key risk factors?
With a beta of 0.49, CVX exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -10.9% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.1% of total portfolio loss in the worst 5% of months. Net margins of 5.9% fall below the Energy sector average of 10%, suggesting margin pressure. The balance sheet is conservatively leveraged at 24% debt-to-equity.
At 0.26, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied and realized volatility are roughly aligned at 27.6% and 27.4% respectively. Insiders have been net sellers to the tune of $345.7M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.1% of float, suggesting limited bearish conviction.
How does CVX fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — CVX carries a beta of 0.49, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, CVX shows the strongest co-movement with XOM (0.83), COP (0.81), EOG (0.75). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios. With the top peer correlation at 0.83, adding CVX to a portfolio that already holds these names provides limited marginal diversification benefit — particularly during stress events when correlations converge toward 1.0.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The CVX analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning CVX’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
